



Press release

June 24, 2024

## **BTB Therapeutics Raises Funds from SMBC Venture Capital**

BTB Therapeutics Co., Ltd. (Representative Directors: Tsuyoshi Ogiku and Takashi Kiyozumi, Registered Office: Kyoto, Japan) has raised funds through a convertible note from the Investment Limited Partnership under management of SMBC Venture Capital Co. Ltd.. This financing follows last year's investments from the Kyogin “Kagayaku Mirai (Shining Future)” Support Fund No. 3 for SDGs, and from Kyoto University Innovation Capital Co., Ltd. (Kyoto iCAP).

Since its founding in 2020, BTB has been developing ENDOPIN, a non-opioid pain compound, and small molecule compounds targeting RNA splicing for the treatment of rare diseases and immunotherapy indications for cancer. Through this financing, we will promote the clinical development of ENDOPIN as the leading asset.

### **Koji Muraoka, General Manager, Investment Department III (Osaka) of SMBC Venture Capital Co. Ltd., commented:**

We are proud to support the development of BTB's programs that address urgent unmet medical needs in healthcare and social issues such as the opioid crisis, rare diseases, and cancer.

### **BTB Representative director, Tsuyoshi Ogiku, commented:**

We are very pleased that this financing will accelerate the development of our pipeline, especially the clinical development of ENDOPIN, a non-opioid analgesic compound. The opioid crisis has become a major social issue globally, and we are committed to developing effective medications that can replace opioids as soon as possible.

### **About SMBC Venture Capital Co. Ltd.:**

SMBC Venture Capital Co., Ltd. is an investment firm that aims to provide funding to growing companies to improve people's lives and solve social issues. In addition, SMBC Venture Capital actively supports the management of its portfolio companies and works in unison to enhance the corporate value. We strive to build relationships of trust with management teams and leverage SMBC's network to build bridges between portfolio companies and large corporations, human resources, and experts.



## **BTB Therapeutics Co., Ltd.**

### **About BTB Therapeutics Co., Ltd.:**

BTB Therapeutics Co., Ltd. was established in June 2020 based on the drug discovery programs of Professor Masatoshi Hagiwara of Kyoto University. We are engaged in the research and development of ENDOPIN, a First-in-Class non-opioid analgesics, as well as small molecules targeting abnormal RNA splicings for the treatment of rare diseases and cancer immunotherapy. Our goal is to create innovative new drugs to address unmet medical needs. Since our inception, we have been awarded multiple grants from the Japan Agency for Medical Research and Development (AMED) and Kyoto Prefecture, totaling approximately 5 billion yen in public financial support.

Representative Directors: Tsuyoshi Ogiku and Takashi Kiyozumi

Date of establishment: June 29, 2020

Website: <https://btb-newdrug.co.jp/en>

For inquiries regarding this release, please contact: [info@btb-newdrug.co.jp](mailto:info@btb-newdrug.co.jp)